The adaptive design of the MARIO-8 study is intended to optimize the dose of the oral drug candidate, eganelisib, in combination with the standard dose of Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab), in 40-70 patients in Part A of the study. 

The dose optimization phase of the study will evaluate two dose regimens of eganelisib; a 30mg regimen, dosed daily for two out of every three weeks, and a 20mg regimen, with continuous daily dosing. 

The selected eganelisib dose, in combination with pembrolizumab, will be further evaluated in Part B of the study in approximately 100 additional patients, with the primary endpoint of overall survival and secondary endpoints of progression-free survival and safety.

Infinity said that a second leading independent proxy advisory firm, Glass, Lewis & Co has joined Institutional Shareholder Services Inc in recommending that stockholders of Infinity and MEI vote FOR the merger.

Price Action: INFI shares are up 19.80% at $0.24 on the last check Monday.